中华医学杂志
中華醫學雜誌
중화의학잡지
National Medical Journal of China
2013年
14期
1076-1079
,共4页
陈卓昌%丁娟娟%钱皓瑜%林香花%冯可青%王静
陳卓昌%丁娟娟%錢皓瑜%林香花%馮可青%王靜
진탁창%정연연%전호유%림향화%풍가청%왕정
糖皮质激素类%茶碱%哮喘%投药,吸入
糖皮質激素類%茶堿%哮喘%投藥,吸入
당피질격소류%다감%효천%투약,흡입
Glucocorticoids%Theophylline%Asthma%Administration,inhalation
目的 探讨吸入性糖皮质激素(ICS)联合小剂量茶碱对未控制支气管哮喘的治疗效果.方法 筛选郑州大学人民医院门诊2011年1至12月门诊未控制支气管哮喘患者280例,用简单随机化分组平均分为试验组和对照组.试验组吸入布地奈德,200μg/吸,2吸/d,联合口服氨茶碱片0.1g,3次/d；对照组吸入布地奈德福莫特罗粉吸入剂(160 μg/4.5 μg)/吸,2吸/d；疗程均为6个月.比较两组患者治疗前后第1秒用力呼气容量占预计值百分比(FEV1％预计值)、外周静脉血白细胞介素(IL)-4、IL-5、IgE值的变化.结果 对照组(134例)及试验组(132例)患者平均年龄分别为(46±13)、(47±12)岁,男女构成比为1∶1.两组治疗前和治疗6个月后的FEV1％预计值、IL-4、IL-5、IgE值:试验组分别为68％±6％和76％±6％,(14.5±4.4)和(7.2±2.6) ng/L,(27.4±6.2)和(24.2±5.9)ng/L,(771±130)×103和(592±104) ×103 U/L,对照组分别为66％±8％和77％±6％,(13.7±4.3)和(7.7±4.0)ng/L,(26.9±5.8)和(24.6±4.8)ng/L,(752±154)×103和(604±122) ×103 U/L;两组治疗前比较差异均无统计学意义(均P＞0.05),治疗后两组组内比较差异均有统计学意义(均P＜0.05),组间比较差异均无统计学意义(均P＞0.05).结论 ICS联合茶碱,在改善哮喘患者肺功能、控制气道炎症方面与ICS联合长效β2受体激动剂有相似的疗效.
目的 探討吸入性糖皮質激素(ICS)聯閤小劑量茶堿對未控製支氣管哮喘的治療效果.方法 篩選鄭州大學人民醫院門診2011年1至12月門診未控製支氣管哮喘患者280例,用簡單隨機化分組平均分為試驗組和對照組.試驗組吸入佈地奈德,200μg/吸,2吸/d,聯閤口服氨茶堿片0.1g,3次/d；對照組吸入佈地奈德福莫特囉粉吸入劑(160 μg/4.5 μg)/吸,2吸/d；療程均為6箇月.比較兩組患者治療前後第1秒用力呼氣容量佔預計值百分比(FEV1％預計值)、外週靜脈血白細胞介素(IL)-4、IL-5、IgE值的變化.結果 對照組(134例)及試驗組(132例)患者平均年齡分彆為(46±13)、(47±12)歲,男女構成比為1∶1.兩組治療前和治療6箇月後的FEV1％預計值、IL-4、IL-5、IgE值:試驗組分彆為68％±6％和76％±6％,(14.5±4.4)和(7.2±2.6) ng/L,(27.4±6.2)和(24.2±5.9)ng/L,(771±130)×103和(592±104) ×103 U/L,對照組分彆為66％±8％和77％±6％,(13.7±4.3)和(7.7±4.0)ng/L,(26.9±5.8)和(24.6±4.8)ng/L,(752±154)×103和(604±122) ×103 U/L;兩組治療前比較差異均無統計學意義(均P＞0.05),治療後兩組組內比較差異均有統計學意義(均P＜0.05),組間比較差異均無統計學意義(均P＞0.05).結論 ICS聯閤茶堿,在改善哮喘患者肺功能、控製氣道炎癥方麵與ICS聯閤長效β2受體激動劑有相似的療效.
목적 탐토흡입성당피질격소(ICS)연합소제량다감대미공제지기관효천적치료효과.방법 사선정주대학인민의원문진2011년1지12월문진미공제지기관효천환자280례,용간단수궤화분조평균분위시험조화대조조.시험조흡입포지내덕,200μg/흡,2흡/d,연합구복안다감편0.1g,3차/d；대조조흡입포지내덕복막특라분흡입제(160 μg/4.5 μg)/흡,2흡/d；료정균위6개월.비교량조환자치료전후제1초용력호기용량점예계치백분비(FEV1％예계치)、외주정맥혈백세포개소(IL)-4、IL-5、IgE치적변화.결과 대조조(134례)급시험조(132례)환자평균년령분별위(46±13)、(47±12)세,남녀구성비위1∶1.량조치료전화치료6개월후적FEV1％예계치、IL-4、IL-5、IgE치:시험조분별위68％±6％화76％±6％,(14.5±4.4)화(7.2±2.6) ng/L,(27.4±6.2)화(24.2±5.9)ng/L,(771±130)×103화(592±104) ×103 U/L,대조조분별위66％±8％화77％±6％,(13.7±4.3)화(7.7±4.0)ng/L,(26.9±5.8)화(24.6±4.8)ng/L,(752±154)×103화(604±122) ×103 U/L;량조치료전비교차이균무통계학의의(균P＞0.05),치료후량조조내비교차이균유통계학의의(균P＜0.05),조간비교차이균무통계학의의(균P＞0.05).결론 ICS연합다감,재개선효천환자폐공능、공제기도염증방면여ICS연합장효β2수체격동제유상사적료효.
Objective To explore the therapeutic efficacies of inhaled corticosteroids (ICS) plus low-dose theophylline for moderate bronchial asthma.Methods A total of 280 patients with moderate bronchial asthma at People's Hospital of Zhengzhou University between January 2011 and December 2011 were recruited and randomized into 2 groups:observation group with inhaled budesonide 400 μ.g/d plus aminophylline tablet (0.1 g,3 times/day,oral administration and control group with inhaled budesonide 320 μg/day plus formoterol 9 μg/day.The course of treatment was around 6 months.The forced expiratory volume in one second ％ predicted (FEV1 ％ predicted),interleukin (IL)-4,IL-5 and IgE of peripheral blood were compared before and after treatment.Results Before and 6 months after treatment,the values of FEV1 ％ predicted,IL-4,IL-5 and IgE for the observed group were 68％ ± 6％ and 76％ ± 6％,(14.5 ±4.4)and(7.2 ±2.6)ng/L,(27.4 ±6.2)and(24.2 ±5.9)ng/L,(771 ± 130) × 103 and(592 ± 104) × 103 U/L,respectively,while those for the control group were 66％ ± 8％ and 77％ ± 6％,(13.7 ± 4.3) and (7.7 ±4.0)ng/L,(26.9 ± 5.8)and (24.6 ± 4.8)ng/L,(752 ± 154)and (604 ± 122) × 103 U/L,respectively.There were significant improvements in both groups (all P ＜ 0.05).No differences existed between two groups (all P ＞ 0.05).Conclusion Compared with ICS plus inhaled long-acting β2-agonists (LABA),ICS plus low-dose theophylline shows similar efficacies in the improvement of lung function and the control of airway inflammation for asthmatics.
